Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-024213
Filing Date
2025-08-14
Accepted
2025-08-14 17:29:11
Documents
74
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1490092
2 EX-31.1 ex31-1.htm EX-31.1 12306
3 EX-31.2 ex31-2.htm EX-31.2 12206
4 EX-32.1 ex32-1.htm EX-32.1 6683
5 EX-32.2 ex32-2.htm EX-32.2 6761
  Complete submission text file 0001641172-25-024213.txt   8172629

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE qlgn-20250630.xsd EX-101.SCH 66617
7 XBRL CALCULATION FILE qlgn-20250630_cal.xml EX-101.CAL 60116
8 XBRL DEFINITION FILE qlgn-20250630_def.xml EX-101.DEF 293543
9 XBRL LABEL FILE qlgn-20250630_lab.xml EX-101.LAB 489771
10 XBRL PRESENTATION FILE qlgn-20250630_pre.xml EX-101.PRE 404474
76 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1451318
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37428 | Film No.: 251221244
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)